ArticleViruses2022
Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8NPJ vaccines · 2026Article
- Ten-year evaluation of HPV vaccine influence on non-vaccine-type-related cervical infections and precancers in Chinese females: follow-up from a randomized control trial.Journal of the National Cancer Center · 2025Article
- HPV infection trends in Inner Mongolia across the pre- and pandemic periods of COVID-19: A single-center analysis.Medicine · 2025Article
- Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva.The American journal of surgical pathology · 2025Article
- Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.Viruses · 2024Review
- HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic.Human vaccines & immunotherapeutics · 2023Article
- Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.EMBO molecular medicine · 2023Article
- Malignancy Associated with Low-Risk HPV6 and HPV11: A Systematic Review and Implications for Cancer Prevention.Cancers · 2023Review
- Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore.Cancers · 2023Article
- Raman Spectroscopy for Early Detection of Cervical Cancer, a Global Women's Health Issue-A Review.Molecules (Basel, Switzerland) · 2023Review
- Confronting the human papillomavirus-HIV intersection: Cervical cytology implications for Kenyan women living with HIV.Southern African journal of HIV medicine · 2023Article
- The health system and access to treatment in patients with cervical cancer in Mexico.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/45/52/58), from 2015. Many studies have now confirmed their ability to prevent infection with vaccine-covered HPV types, and the subsequent development of either genital warts and/or cervical neoplasia, although this is clearly more effective in younger women vaccinated prior to sexual debut. Most notably, reductions in the prevalence of vaccine-covered HPV types were also observed in unvaccinated women at the same geographical location, presumably by sexual dissemination of these changes, between vaccinated and unvaccinated women. Furthermore, there are several studies that have demonstrated vaccine-associated HPV type-replacement, where vaccine-covered, high-risk HPV types are replaced by high-risk HPV types not covered by the vaccines, and these changes were also observed in vaccinated and unvaccinated women in the same study population. In light of these observations, it is not entirely clear what effects vaccine-associated HPV type-replacement will have, particularly in older, unvaccinated women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.